Vantage Biosciences
CompanyUnited Kingdom
Vantage Biosciences develops one asset, in phase 2 (VX-01 in diabetic retinopathy). Mostly small molecule acting on inflammation; based in the United Kingdom.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 0
- Signals
Pipeline
1Oral inhibitor of vascular inflammatory signaling for diabetic retinopathy
Phase 2, Small molecule, Inflammation, diabetic retinopathy, NPDR - non proliferative diabetic retinopathy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Similar companies6